Furthermore, another study reported MDSCs as the primary source of IL-6 in severe COVID-19, but administering tocilizumab (an IL-6 inhibitor) did not reduce circulating MDSC or IL-6 levels. This evidence concerns the gene IL6 and COVID-19.